mRNA translation (eIF4F / mTOR)
Cancer cells must make protein at furious speed. The eIF4F complex that starts protein synthesis is the funnel where growth signals converge, and drugs that pinch the funnel starve the tumour of the proteins it needs most.
mTORC1 phosphorylates 4E-BPs, releasing eIF4E to form eIF4F (eIF4E/4G/4A) and translate cap-dependent, oncogene-rich mRNAs (MYC, cyclin D1, BCL-2, MCL-1); MNK kinases phosphorylate eIF4E. Ribosomal protein and rRNA synthesis (POLR1, RNA pol I inhibitors such as CX-5461) are collateral dependencies. Drugs: eIF4A inhibitors (zotatifin, phase 1/2 in ER+ breast and KRAS-mutant cancers), MNK inhibitors (tomivosertib), mTOR inhibitors (everolimus approved), and RNA pol I inhibitors in BRCA/HRD (CX-5461 with PARP). Translation control is a shared node downstream of PI3K, RAS, and MYC.
In one picture
A factory's single loading dock (eIF4F). No matter how many orders the managers (RAS, PI3K, MYC) shout, everything must pass through the dock. Narrow the dock and the most urgent, oversized orders (oncogene proteins) are the first to fail.
Diagram
top- mTOR inhibitors (everolimus) approved in breast, RCC, NET
- eIF4A inhibitor zotatifin (eFT226) phase 1/2 with fulvestrant/abemaciclib
- MNK inhibitors (tomivosertib) in NSCLC (mixed)
- RNA Pol I inhibitors (CX-5461, pidnarulex) in HRD cancers
Notes
top- Leading programmes: Sonenberg (McGill); Ruggero (UCSF) on translation control in cancer; Pelletier (McGill) on eIF4A; eFFECTOR Therapeutics.
Pages like this
not linked directly; found by shared links- PathwayHippo–YAP/TAZ
Shares Massachusetts General Hospital Cancer Center, RAS / RAF / MEK / ERK (MAPK), Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayCancer metabolism
Shares MYC, PIK3CA / PI3K-alpha, PI3K / AKT / mTOR, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayCircadian control
Shares MYC, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayAutophagy
Shares PI3K / AKT / mTOR, RAS / RAF / MEK / ERK (MAPK) and the tag mechanism.
- PathwayKEAP1–NRF2 antioxidant pathway
Shares RAS / RAF / MEK / ERK (MAPK), Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayRNA splicing
Shares MYC, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayInflammation & NF-κB
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayTelomere maintenance & replicative immortality
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag mechanism.